Table 1 Clinical and demographic data of patients
From: Excellent long-term outcome of renal transplantation in cystinosis patients
cystinosis (n = 31) | control (n = 93) | ||
|---|---|---|---|
Male / Female | 16/15 | 59 / 34 | |
Age at ESRD (years) | 18.8 (7.7-35.0) | 19.8 (4.0-32.0) | p = 0.07 |
Age at transplantation (years) | 20.4 (7.1-36.5) | 21.8 (13.6-32.0) * | p = 0.03 |
Patient <19 yearsold (n=) | 15 (48.4 %) | 12 (12.9 %) * | P < 0.001 |
Time from dialysis to transplantation (years) | 1.3 (0.12-8.0) | 1.6 (0.1-19.0) | p = 0.1 |
Preemptive transplantation (n=) | 9 (29.0 %) | 12 (13.0 %) | p = 0.06 |
Transplantation rank | 1 (n = 25); 2 (n = 6) | 1 (n = 75); 2 (n = 17) | |
BMI (kg/m2) | 19.0 (14.3-28.7) | 19.9 (14.0-25.0) | p = 0.4 |
Diabetesmellitus (n=) | 3 (9.7 %) | 2 (2 %) | p = 0.1 |
Initial graft data | |||
Living kidney donation (n=) | 9 (29.0 %) | 26 (28.6 %) | p = 1 |
Deceased donor age (years) | 30.0 (0.6-64.0) | 37.0 (10.0-62.0) * | p < 0.05 |
Extended criteria donor (n=) | 1 (3.2 %) | 3 (3.2 %) | p = 1 |
Delayed graft function (n=) | 4 (13.0 %) | 18 (19.0 %) | p = 0.6 |
Cold ischemia (hours) | 17.5 (0.6-43.0) | 17.5 (0.5-47.0) | p = 0.4 |
Donor specific antibody presence (n=) | 4 (13.0 %) | 13 (14.0 %) | p = 1 |
Induction treatment | |||
Steroids (n=) | 30 (97.0 %) | 93 (100 %) | p = 0.3 |
Mycophenolate mofetil (n=) | 18 (58.0 %) | 53 (57.0 %) | p = 1 |
Azathrioprine (n=) | 13 (42.0 %) | 15 (16.0 %)* | p 0.006 |
Ciclosporine A (n=) | 14 (45.0 %) | 53 (57.0 %) | p = 0.3 |
Tacrolimus (n=) | 17 (55.0 %) | 35 (37.6 %) | p = 0.1 |
OKT3 (n=) | 0 | 5 (5.4 %) | p = 0.30 |
Thymoglobulin (n=) | 18 (58.0 %) | 53 (57.0 %) | p = 1 |
Basiliximab (n=) | 13 (42.0 %) | 35 (37.6 %) | p = 0.7 |
Follow up | |||
Duration of follow up (months) | 144.1 (5.9-340.6) | 72.0 (0.1-240.0) * | p < 0.0001 |
Age at last follow up (months) | 32.7 (18.7-54.5) | 29.7 (18.7-43.3) * | p = 0.01 |
ESRD at last follow up (n=) | 6 (19.4 %) | 29 (31.0 %) | p = 0.3 |
eGFR (MDRD) at 180 months (mL/min/1.73 m2) | 53.7 (19.0-103.0) | 47.4 (7.7-111.4) | p = 0.18 |
Maintenance treatment | |||
Stop of steroid during first year (n=) | 3 (9.7 %) | 15 (16.0 %) | p = 0.6 |
Mycophenolate mofetil (n=) | 15 (48.3 %) | 43 (46.2 %) | p = 0.84 |
Azathrioprine (n=) | 8 (25.8 %) | 25 (26.8 %) | p = 1 |
Ciclosporine A (n=) | 15 (48.0 %) | 41 (44.0 %) | p = 0.7 |
Tacrolimus (n=) | 14 (45.0 %) | 33 (35.0 %) | p = 0.4 |
Everolimus (n=) | 1 (3.0 %) | 2 (2.0 %) | p = 1 |
Graft complication | |||
Graft rejection (n=) | 8 (26.0 %) | 30 (32.0 %) | p = 0.7 |
Infections (n=) | 14 (45.0 %) | 56 (60.0 %) | p = 0.2 |
PTDM (n=) | 4 (13.0 %) | 5 (5.0 %) | p = 0.2 |
Stroke (n=) | 1 (3.0 %) | 0 | p = 0.3 |
Myocardial infarction (n=) | 0 | 1 (1.0 %) | p = 1 |
Death (n=) | 1 (3.0 %) | 2 (2.0 %) | p = 1 |